Loading company…
Princeton-based PMV Pharmaceuticals develops therapies that target the p53 protein in cancers such as breast, lung and colorectal.
Founded in 2013, the company raised USD 211.7 mn in an IPO on September 24, 2020. Its product candidates are in clinical trials, and it earns revenue from partnerships through milestone payments, royalties and co-development agreements.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in